Home・Akcijų sąrašas・Gossamer Bio Inc

Gossamer Bio Inc

Atidarymo kaina

SektoriusSveikatos priežiūra

0.18 5.88

Pirkti Parduoti

Apžvalga

Akcijų kainos pasikeitimas

24 val.

Dabar

Min

0.16

Max

0.18

Pagrindiniai rodikliai
By Trading Economics
Pajamos	574K -47M
Pardavimai	3.2M 17M
Pelnas, tenkantis vienai akcijai	-0.2
Pelno marža	-275.223
Darbuotojai	161
EBITDA	2.1M -44M

Rekomendacijos
By TipRanks
Rekomendacijos	Neutralu
12 mėnesių prognozė	+529.41% upside

Dividendai
By Acuity
Kitas uždarbis	2026-08-10

Rinkos statistika
By TradingEconomics
Rinkos kapitalizacija	18M 97M
Ankstesnė atidarymo kaina	-5.7
Ankstesnė uždarymo kaina	0.18

Naujienos nuotaikos

By Acuity

63%

37%

285 / 340 reitingas Healthcare

Gossamer Bio Inc Grafikas

Ankstesni rezultatai nėra patikimas būsimų rezultatų rodiklis.

Susijusios naujienos

2026-08-03 23:06; UTC

Gossamer Bio Inc. shares remained roughly flat in after-market hours, with no specific news identified. Broader market sentiment improved following strong manufacturing data.

2026-08-01 00:02; UTC

Social Media

Gossamer Bio Inc shares are lower in after-market hours, continuing a downward trend following recent gains tied to an FDA update on Seralutinib.

2026-07-31 23:41; UTC

Social Media

Gossamer Bio Inc. shares are higher in after-market trading following an FDA update on Seralutinib, its candidate for pulmonary arterial hypertension.

2026-07-30 23:02; UTC

Gossamer Bio Inc is higher in after-market hours, reflecting broader market gains. The stock benefits from positive sentiment in the biotech sector.

2026-07-29 22:31; UTC

Gossamer Bio Inc. shares declined in after-market hours, reflecting unusual movement despite being above its 20-day moving average and near a one-month range high.

2026-07-28 23:41; UTC

Gossamer Bio Inc. shares are lower in after-market hours amid broader market declines, particularly in Asia's technology sector due to AI spending concerns.

2026-07-27 23:51; UTC

Social Media

Gossamer Bio Inc shares are higher in after-market trading following an upgrade to Outperform from Leerink and an FDA regulatory update on Seralutinib.

2026-07-24 22:01; UTC

Gossamer Bio Inc shares rose during after-market trading, reflecting notable strength despite mixed global equity market performance and without any specific company news identified.

2026-07-23 23:01; UTC

Gossamer Bio Inc's shares are higher in after-market trading, recovering from earlier losses despite no specific news to explain the movement.

2026-07-22 23:01; UTC

Gossamer Bio Inc shares are higher in after-market trading, reflecting a notable rise since Wednesday's close amid rising crude oil prices and geopolitical tensions.

2026-07-21 21:01; UTC

Gossamer Bio Inc shares are higher in after-market hours, buoyed by positive sentiment from better-than-expected second-quarter results across major companies.

2026-07-20 23:01; UTC

Gossamer Bio Inc shares are trading higher in after-market hours, despite no specific news, amid broader market volatility and inflation concerns.

Akcijų palyginimas

Kainos pokytis

Gossamer Bio Inc Prognozė

Kainos tikslas

By TipRanks

529.41% į viršų

12 mėnesių prognozė

Vidutinis 1.07 USD 529.41%

Aukščiausias 2 USD

Žemiausias 0.28 USD

Remiantis 5 „Wall Street“ analitikais, siūlančiais 12 mėnesių tikslines Gossamer Bio Inc kainas – Dist per pastaruosius 3 mėnesius.

Bendras įvertinimas

By TipRanks

Neutralu

5 ratings

Pirkti

Laikyti

Parduoti

Remiantis 5 analitikų, pateikusių Gossamer Bio Inc akcijų reitingus – Dist per pastaruosius 3 mėnesius.

Rinkos nuotaikos

By Acuity

285 / 340 reitingas Sveikatos priežiūra

Finansinės naujienos

Pardavimo ir administravimo išlaidos

Veiklos sąnaudos

Ikimokestinis pelnas

Pardavimai

Pardavimo savikaina

Bendrasis pelnas iš pardavimo

Skolų palūkanų išlaidos

EBITDA

Veiklos pelnas

Apie bendrovę Gossamer Bio Inc

Gossamer Bio, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing seralutinib for the treatment of pulmonary arterial hypertension (PAH) in the United States. The company is developing GB002, an inhaled, small molecule, platelet-derived growth factor receptor, or PDGFR, colony-stimulatin factor 1 receptor and c-KIT inhibitor, which is in Phase 3 clinical trial for the treatment of PAH. It has license agreements with Pulmokine, Inc. to develop and commercialize GB002 and related backup compounds. The company was formerly known as FSG, Bio, Inc. and changed its name to Gossamer Bio, Inc. in 2017. Gossamer Bio, Inc. was incorporated in 2015 and is headquartered in San Diego, California.